Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
This is not a financial advice!
2 upcoming catalysts on 31st of March and a few more in 2024
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
6.0 needs to get broken - big resistance - SMA 200
Keep an eye on 7.0 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 5.0
TP approx. 9.0
Most info on the chart.
Trade carefully!
This is not a financial advice!
2 upcoming catalysts on 31st of March and a few more in 2024
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
6.0 needs to get broken - big resistance - SMA 200
Keep an eye on 7.0 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 5.0
TP approx. 9.0
Most info on the chart.
Trade carefully!
코멘트:
smellllll
거래청산: 타겟 닿음:
Stoke Therapeutics Announces New Data Supporting Potential For STK-001 To Be First Disease-Modifying Medicine For Treatment Of Patients With Dravet Syndrome
BOOOOOM
BOOOOOM